112 related articles for article (PubMed ID: 30483769)
1. IKBKB expression in clear cell renal cell carcinoma is associated with tumor grade and patient outcomes.
Krazinski BE; Kowalczyk AE; Sliwinska-Jewsiewicka A; Grzegrzolka J; Godlewski J; Kwiatkowski P; Dziegiel P; Kmiec Z; Kiewisz J
Oncol Rep; 2019 Feb; 41(2):1189-1197. PubMed ID: 30483769
[TBL] [Abstract][Full Text] [Related]
2. Tumor biology of non-metastatic stages of clear cell renal cell carcinoma; overexpression of stearoyl desaturase-1, EPO/EPO-R system and hypoxia-related proteins.
Stoyanoff TR; Rodríguez JP; Todaro JS; Espada JD; Colavita JP; Brandan NC; Torres AM; Aguirre MV
Tumour Biol; 2016 Oct; 37(10):13581-13593. PubMed ID: 27468719
[TBL] [Abstract][Full Text] [Related]
3. RAC2 acts as a prognostic biomarker and promotes the progression of clear cell renal cell carcinoma.
Liu Y; Cheng G; Song Z; Xu T; Ruan H; Cao Q; Wang K; Bao L; Liu J; Zhou L; Liu D; Yang H; Chen K; Zhang X
Int J Oncol; 2019 Sep; 55(3):645-656. PubMed ID: 31364727
[TBL] [Abstract][Full Text] [Related]
4. High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma.
Wu XR; Sha JJ; Liu DM; Chen YH; Yang GL; Zhang J; Chen YY; Bo JJ; Huang YR
Eur J Surg Oncol; 2013 Jan; 39(1):100-6. PubMed ID: 23102595
[TBL] [Abstract][Full Text] [Related]
5. Alpha-enolase is a potential prognostic marker in clear cell renal cell carcinoma.
White-Al Habeeb NM; Di Meo A; Scorilas A; Rotondo F; Masui O; Seivwright A; Gabril M; Girgis AH; Jewett MA; Yousef GM
Clin Exp Metastasis; 2015 Aug; 32(6):531-41. PubMed ID: 26037892
[TBL] [Abstract][Full Text] [Related]
6. Reduced expression of growth and differentiation factor-9 (GDF9) is associated with aggressive behaviour of human clear-cell renal cell carcinoma and poor patient survival.
Du P; Ye L; Yang Y; Jiang WG
Anticancer Res; 2014 Nov; 34(11):6515-20. PubMed ID: 25368253
[TBL] [Abstract][Full Text] [Related]
7. Kinome expression profiling identifies IKBKE as a predictor of overall survival in clear cell renal cell carcinoma patients.
Hildebrandt MA; Tan W; Tamboli P; Huang M; Ye Y; Lin J; Lee JS; Wood CG; Wu X
Carcinogenesis; 2012 Apr; 33(4):799-803. PubMed ID: 22266464
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
[TBL] [Abstract][Full Text] [Related]
9. PLAGL1 (ZAC1/LOT1) Expression in Clear Cell Renal Cell Carcinoma: Correlations with Disease Progression and Unfavorable Prognosis.
Godlewski J; Krazinski BE; Kowalczyk AE; Kiewisz J; Kiezun J; Kwiatkowski P; Sliwinska-Jewsiewicka A; Maslowski Z; Kmiec Z
Anticancer Res; 2016 Feb; 36(2):617-24. PubMed ID: 26851016
[TBL] [Abstract][Full Text] [Related]
10. Cytoplasmic expression of Twist1, an EMT-related transcription factor, is associated with higher grades renal cell carcinomas and worse progression-free survival in clear cell renal cell carcinoma.
Rasti A; Madjd Z; Abolhasani M; Mehrazma M; Janani L; Saeednejad Zanjani L; Asgari M
Clin Exp Med; 2018 May; 18(2):177-190. PubMed ID: 29204790
[TBL] [Abstract][Full Text] [Related]
11. High TXNDC5 expression predicts poor prognosis in renal cell carcinoma.
Mo R; Peng J; Xiao J; Ma J; Li W; Wang J; Ruan Y; Ma S; Hong Y; Wang C; Gao K; Fan J
Tumour Biol; 2016 Jul; 37(7):9797-806. PubMed ID: 26810069
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of CTR2 predicts poor prognosis of patients with clear cell renal cell carcinoma.
Xia Y; Liu L; Long Q; Bai Q; Wang J; Xu J; Guo J
Urol Oncol; 2016 Jan; 34(1):5.e1-9. PubMed ID: 26411550
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of platelet-derived growth factor receptor-β expression in localized clear cell renal cell carcinoma.
Shim M; Song C; Park S; Choi SK; Cho YM; Kim CS; Ahn H
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2213-20. PubMed ID: 26215891
[TBL] [Abstract][Full Text] [Related]
14. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.
Ambrosetti D; Dufies M; Dadone B; Durand M; Borchiellini D; Amiel J; Pouyssegur J; Rioux-Leclercq N; Pages G; Burel-Vandenbos F; Mazure NM
PLoS One; 2018; 13(2):e0193477. PubMed ID: 29481555
[TBL] [Abstract][Full Text] [Related]
15. Low level of isocitrate dehydrogenase 1 predicts unfavorable postoperative outcomes in patients with clear cell renal cell carcinoma.
Laba P; Wang J; Zhang J
BMC Cancer; 2018 Aug; 18(1):852. PubMed ID: 30153799
[TBL] [Abstract][Full Text] [Related]
16. Enhanced IMP3 Expression Activates NF-кB Pathway and Promotes Renal Cell Carcinoma Progression.
Pei X; Li M; Zhan J; Yu Y; Wei X; Guan L; Aydin H; Elson P; Zhou M; He H; Zhang H
PLoS One; 2015; 10(4):e0124338. PubMed ID: 25919292
[TBL] [Abstract][Full Text] [Related]
17. Altered Expression of DDR1 in Clear Cell Renal Cell Carcinoma Correlates With miR-199a/b-5p and Patients' Outcome.
Krazinski BE; Kiewisz J; Sliwinska-Jewsiewicka A; Kowalczyk AE; Grzegrzolka J; Godlewski J; Kwiatkowski P; Dziegiel P; Kmiec Z
Cancer Genomics Proteomics; 2019; 16(3):179-193. PubMed ID: 31018949
[TBL] [Abstract][Full Text] [Related]
18. Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma.
Saeednejad Zanjani L; Madjd Z; Abolhasani M; Andersson Y; Rasti A; Shariftabrizi A; Asgari M
Exp Mol Pathol; 2017 Oct; 103(2):218-228. PubMed ID: 29050853
[TBL] [Abstract][Full Text] [Related]
19. TGF-β-activated kinase-1: a potential prognostic marker for clear cell renal cell carcinoma.
Wei C; Lai YQ; Li XX; Ye JX
Asian Pac J Cancer Prev; 2013; 14(1):315-20. PubMed ID: 23534745
[TBL] [Abstract][Full Text] [Related]
20. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
